Advertisement
BN vs IVZ
Which Stock Would AI Choose? Brookfield Corporation (BN) vs. Invesco (IVZ) Stock Comparison
Key Takeaways
- BN is a diversified alternative-asset manager and owner-operator of real assets, while IVZ is a traditional global asset manager with a heavy tilt toward ETFs and passive products.
- IVZ has shown stronger recent momentum, with assets under management (AUM) rising roughly 23% year over year and record net long-term inflows.
- BN is reaccelerating earnings growth and simplifying its corporate structure, but its shares have lagged over the past year.
- The two firms carry very different risk profiles: BN is tied to private markets and interest-rate-sensitive real assets, while IVZ faces fee compression and market-driven flow volatility.
- Analyst consensus remains a "Buy" on both names, though BN screens with more downside dispersion in forecasts and IVZ offers a notably higher dividend yield.
Introduction
Investors weighing exposure to the asset and wealth management industry often face a choice between pure-play traditional managers and diversified alternative-investment platforms. BN (Brookfield Corporation) and IVZ (Invesco Ltd.) represent two very different ends of that spectrum. This stock comparison examines their business models, recent performance, growth drivers, and risk factors to help traders and investors understand how their relative performance and market positioning have diverged in the current environment. Both experienced meaningful catalysts in recent quarters, yet their price behavior and sentiment have followed distinct paths.
BN Overview and Recent Performance
BN (Brookfield Corporation) is a Toronto-headquartered global investment firm that owns and operates real assets across infrastructure, renewable power, real estate, private equity, and credit and insurance solutions. In its most recent quarter, the company reported distributable earnings before realizations of approximately $1.4 billion, up about 7% year over year, signaling a reacceleration in earnings growth after a flat prior quarter. Fee-bearing capital rose roughly 12% to about $614 billion, supporting an 11% increase in fee-related earnings.
Recent weeks have been defined by structural simplification and expansion. BN advanced plans to combine with Brookfield Wealth Solutions to create an integrated insurance and investment business, and completed the acquisition of U.K.-based Just Group, lifting insurance assets by roughly $40 billion to about $180 billion. The firm also continues to deploy capital into AI infrastructure, including a $500 million strategic partnership with OpenAI. Despite these catalysts, BN shares have declined over the past year, with analyst price targets sitting well above the recent share price even as some valuation models flag the stock as extended.
IVZ Overview and Recent Performance
IVZ (Invesco Ltd.) is an Atlanta-based global asset manager serving clients in more than 120 countries, with a diversified lineup spanning ETFs, index strategies, fundamental equities, fixed income, private markets, and money market funds. The firm's AUM (assets under management) has climbed sharply, reaching roughly $2.47 trillion in its latest quarter, up about 23% year over year, driven by favorable markets and record net long-term inflows.
A defining recent development was the restructuring of the firm's flagship QQQ product from a unit investment trust into an open-end ETF, which reshaped revenue and expense recognition while reinforcing IVZ's position in the large and fast-growing ETF category. Adjusted diluted earnings per share (EPS) rose roughly 30% year over year in the first quarter and nearly doubled in the second quarter, supported by a 300-basis-point improvement in adjusted operating margin. Shares have delivered a strong one-year total return, though near-term price momentum has cooled amid softer monthly AUM readings and lingering fee-compression concerns in passive products.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page offers a curated view of the platform's most compelling automated strategies. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only the best and most suitable for current market conditions earn a place in this featured section. These bots span a wide range of trading styles, strategies, timeframes, performance metrics, and statistical profiles, each tracking its own distinct set of tickers. By focusing on trend consistency, win rates, and recent performance, the curated list helps traders quickly identify strategies aligned with prevailing market dynamics. Explore the Trending AI Robots to see which automated approaches are currently standing out.
Head-to-Head Comparison
Although both companies operate in financial services, their business models are fundamentally different. BN is an owner-operator that derives value from deploying capital into real assets and capturing carried interest and asset-monetization gains, making its earnings more sensitive to interest rates and private-market valuations. IVZ, by contrast, is a fee-based asset gatherer whose revenue scales with AUM and product mix, exposing it to market beta and structural fee compression from low-cost passive products.
On momentum, IVZ has been the stronger performer recently, posting accelerating AUM growth, record net long-term inflows, and a superior one-year total return. BN offers a more complex, multi-year value-unlocking story built on structural simplification and AI infrastructure, but its share price has lagged earnings growth and sits below most analyst targets. Risk profiles diverge as well: IVZ faces flow volatility and fee pressure, while BN carries leverage, insurance liabilities, and cyclical exposure to real assets. Income-oriented investors may also note IVZ's materially higher dividend yield relative to BN.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor IVZ in the current environment, reflecting its stronger and more consistent recent trend, robust AUM and flow growth, and improving operating margins. These momentum and stability characteristics typically align with the signals prioritized by trend-following models. BN presents a compelling longer-term catalyst story but currently exhibits softer price momentum and greater valuation dispersion, which may reduce its near-term appeal to AI-driven strategies. This assessment is probabilistic rather than definitive and should be considered alongside each investor's own research and objectives.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BN is a Hold and IVZ is a StrongBuy.
BN in +3.86% Uptrend, advancing for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BN advanced for three days, in 225 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on BN as a result. In 50 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
BN moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BN crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
Bearish Trend Analysis
The 10-day RSI Indicator for BN moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 28 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
BN broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BN entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 44 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. BN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.174) is normal, around the industry mean (2.412). P/E Ratio (73.893) is within average values for comparable stocks, (-2.386). Projected Growth (PEG Ratio) (0.110) is also within normal values, averaging (1.319). Dividend Yield (0.007) settles around the average of (0.270) among similar stocks. P/S Ratio (1.135) is also within normal values, averaging (15.694).
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
IVZ sees its Stochastic Oscillator climbs out of oversold territory
On November 04, 2026, the Stochastic Oscillator for IVZ moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 57 instances where the indicator left the oversold zone. In 44 of the 57 cases the stock moved higher in the following days. This puts the odds of a move higher at over 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IVZ's RSI Oscillator exited the oversold zone, 21 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 66%.
Following a +6.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVZ advanced for three days, in 227 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
IVZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IVZ as a result. In 58 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.
The Moving Average Convergence Divergence Histogram (MACD) for IVZ turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 31 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for IVZ entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. IVZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.200) is normal, around the industry mean (2.412). P/E Ratio (-40.418) is within average values for comparable stocks, (-2.386). Projected Growth (PEG Ratio) (0.901) is also within normal values, averaging (1.319). Dividend Yield (0.032) settles around the average of (0.270) among similar stocks. P/S Ratio (1.981) is also within normal values, averaging (15.694).
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
BN | IVZ | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 82 Overvalued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 44 | 57 | |
SMR RATING 1..100 | 87 | 92 | |
PRICE GROWTH RATING 1..100 | 53 | 59 | |
P/E GROWTH RATING 1..100 | 91 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IVZ's Valuation (76) in the Investment Managers industry is in the same range as BN (82). This means that IVZ’s stock grew similarly to BN’s over the last 12 months.
BN's Profit vs Risk Rating (44) in the Investment Managers industry is in the same range as IVZ (57). This means that BN’s stock grew similarly to IVZ’s over the last 12 months.
BN's SMR Rating (87) in the Investment Managers industry is in the same range as IVZ (92). This means that BN’s stock grew similarly to IVZ’s over the last 12 months.
BN's Price Growth Rating (53) in the Investment Managers industry is in the same range as IVZ (59). This means that BN’s stock grew similarly to IVZ’s over the last 12 months.
BN's P/E Growth Rating (91) in the Investment Managers industry is in the same range as IVZ (100). This means that BN’s stock grew similarly to IVZ’s over the last 12 months.
| BN | IVZ | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 68% | 3 days ago 66% |
| Stochastic ODDS (%) | 3 days ago 73% | 3 days ago 77% |
| Momentum ODDS (%) | 3 days ago 63% | 3 days ago 69% |
| MACD ODDS (%) | N/A | 3 days ago 67% |
| TrendWeek ODDS (%) | 3 days ago 67% | 3 days ago 70% |
| TrendMonth ODDS (%) | 3 days ago 61% | 3 days ago 69% |
| Advances ODDS (%) | 11 days ago 66% | 5 days ago 68% |
| Declines ODDS (%) | 3 days ago 66% | 17 days ago 70% |
| BollingerBands ODDS (%) | 3 days ago 67% | 3 days ago 76% |
| Aroon ODDS (%) | 3 days ago 59% | 3 days ago 63% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BN’s FA Score shows that 0 FA rating(s) are green while IVZ’s FA Score has 0 green FA rating(s).
- BN’s FA Score: 0 green, 5 red.
- IVZ’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BN’s TA Score shows that 4 TA indicator(s) are bullish while IVZ’s TA Score has 4 bullish TA indicator(s).
- BN’s TA Score: 4 bullish, 5 bearish.
- IVZ’s TA Score: 4 bullish, 4 bearish.
Price Growth
BN (@Investment Managers) experienced а +5.35% price change this week, while IVZ (@Investment Managers) price change was -2.45% for the same time period.
The average weekly price growth across all stocks in the @Investment Managers industry was -1.02%. For the same industry, the average monthly price growth was -4.60%, and the average quarterly price growth was -5.52%.
Reported Earning Dates
BN is expected to report earnings on Nov 12, 2026.
IVZ is expected to report earnings on Jan 26, 2027.
Industries' Descriptions
@Investment Managers (-1.02% weekly)Investment Managers manage financial assets and other investments of clients. Management includes designing a short- or long-term strategy for buying/holding and selling of portfolio holdings. It can also include tax services and other aspects of financial planning as well. While it is perceived that the industry is faced with growing competition from robo-advisors/digital platforms and passive/ index-tracking funds, many investors still find value in actively managed in-person services that investment management companies often emphasize on. At the same time, many wealth managers are also incorporating digital initiatives/low cost options in addition to their in-person customized services. Their main sources of revenues are fees as a percentage of assets under management, in addition to a certain portion of clients’ gains from asset appreciation. BlackRock, Inc., Blackstone Group Inc and Brookfield Asset Management are some of the major investment management companies.
Advertisement
IVZ and
Correlation & Price change
A.I.dvisor indicates that over the last year, IVZ has been closely correlated with BLK. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if IVZ jumps, then BLK could also see price increases.
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| DIA.X | 0.129304 | -0.006012 | -4.44% |
| DIA cryptocurrency | |||
| FET.X | 0.137225 | -0.006817 | -4.73% |
| Artificial Superintelligence Alliance cryptocurrency | |||
| ACH.X | 0.004171 | -0.000217 | -4.95% |
| Alchemy Pay cryptocurrency | |||
| NPXS.X | 0.000012 | -0.000001 | -5.08% |
| Pundi X (Old) cryptocurrency | |||
| ACM.X | 0.213317 | -0.012863 | -5.69% |
| AC Milan Fan Token cryptocurrency | |||